Compare Costco Wholesale Corporation (COST) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Moderna, Inc. — how do they compare? Costco Wholesale Corporation trades at $922.19 (market cap $408.78B), while Moderna, Inc. trades at $67.61 (market cap $26.76B). The key difference: Costco Wholesale Corporation is far larger — about 15.3× Moderna, Inc.'s market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| COST | MRNA | |
|---|---|---|
Market Cap | $408.78B | $26.76B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $81.80 |
52-Week Low | $849.63 | $22.36 |
Enterprise Value | $396.92B | $22.85B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $926.43, up 1.11% over 24h, with a bearish technical signal but strong fundamentals. Revenue grew to $275.24B in 2025, with net income of $8.10B, though Q1 2026 EPS missed expectations. The stock's valuation is elevated with a P/E of 46.37, while analyst consensus remains bullish with a $1,120 price target. Recent news highlights membership fee hikes and March sales growth of 11.3% year-over-year, indicating resilient consumer demand.
Outlook is mixed: robust membership model and sales trends support growth, but high valuation and technical bearishness pose near-term risks. Investors should weigh strong cash flow and analyst optimism against potential pullbacks from current levels. Key risks include competitive pressures and macroeconomic sensitivity, though institutional buying signals confidence.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
